Empagliflozin and Topiramate combo Effective for Weight Loss in Non-Diabetic Overweight Individuals: Study

Evaluations for weight, height, body mass index (BMI), waist circumference (WC), and body composition were conducted at baseline and weeks 4, 8, and 12. Additionally, blood pressure, C-reactive protein, and parameters related to glucose and lipid profiles were measured before and after the intervention.

The following were the key findings of the study:

• The EMPA/TPM group experienced a greater percentage decrease in weight at week 12 compared to the placebo group (−8.92 ± 1.80 vs. −4.93 ± 1.17). This intervention group also showed a more significant reduction in fat mass and fat percentage.
• There was no notable difference in the change in fat-free percentage between the two groups at week 12.
• Within each group, there was a significant decrease in systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood sugar (FBS), insulin levels, HOMA-IR, total cholesterol (TC), LDL, HDL, triglycerides (TG), and C-reactive protein (CRP).
• Despite these changes, no statistically significant differences were found between the two groups for any of these variables at week 12.

The findings showed that the 12-week administration of EMPA/TPM along with calorie restriction in overweight, non-diabetic patients resulted in a notable decrease in body weight, BMI, and fat mass, with participants generally tolerating the treatment well. However, there were no significant changes in waist circumference, glycemic and lipid profiles, blood pressure, or inflammation between the two groups.

Reference:

Abiri, B., Ramezani Ahmadi, A., Hosseinpanah, F. et al. Randomized study of the effects of empagliflozin and topiramate dual therapy on anthropometric and metabolic indices in non-diabetic individuals with overweight/obesity on a calorie-restricted diet. Eat Weight Disord 29, 64 (2024). https://doi.org/10.1007/s40519-024-01692-2